Show simple item record

dc.contributor.authorElorriaga, Miguel Ángel
dc.contributor.authorNeyro, José Luis
dc.contributor.authorMieza, Jon
dc.contributor.authorCristóbal García, Ignacio 
dc.contributor.authorLlueca, Antoni
dc.date.accessioned2022-02-01T12:50:38Z
dc.date.available2022-02-01T12:50:38Z
dc.date.issued2021
dc.identifier.issn2075-4426spa
dc.identifier.urihttp://hdl.handle.net/10641/2770
dc.description.abstractBackground: Ovarian cancer has a low incidence, but high mortality due to a habitual diagnosis in advanced cancer stages. Currently, used biomarkers have good sensitivity, but low specificity. Aim: To determine the usefulness of the biomarkers and algorithms used up to now in the screening, diagnosis, response to treatments and identification of recurrence in patients with ovarian masses. Methodology: Systematic search of publications in English in the Medline-PubMed database with the terms: “biomarkers”, “tumour”, “tumour biomarkers”, “marker”, “tumour marker”, “ovarian cancer”, “ovarian”, “Neoplasms”, “cancer”, CA-125 Antigen; Human Epididymis-specific Protein E4; Risk of Malignancy Index (RMI); Risk of Ovarian Malignancy Algorithm (ROMA); Ovarian Neoplasms. Original articles, clinical trials, reviews, systematic reviews and meta-analyses, published between January 2000 and November 2020, were selected to determine the usefulness (among others) of CA 125 and HE4 antigen in ovarian cancer. Results: Finally, 39 transcendental publications were selected to write this article to determine the usefulness of tumour markers and algorithms in ovarian cancer. Conclusions: The usefulness of the tumour markers antigen CA125 and antigen HE4 individually or as a basis for decision-making algorithms has low specificity; however, there is little evidence that confirms their usefulness as markers in ovarian cancer screening.spa
dc.language.isoengspa
dc.publisherJournal of Personalized Medicinespa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectBiomarkersspa
dc.subjectTumour markersspa
dc.subjectHE4 antigenspa
dc.subjectOvarian cancerspa
dc.titleBiomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature.spa
dc.typearticlespa
dc.description.versionpost-printspa
dc.rights.accessRightsopenAccessspa
dc.description.extent723 KBspa
dc.identifier.doi10.3390/jpm11111115spa
dc.relation.publisherversionhttps://www.mdpi.com/2075-4426/11/11/1115spa


Files in this item

FilesSizeFormatView
jpm-11-01115-v3.pdf722.6KbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España